AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05951283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Closed Loop Insulin Pump
Description: As above
Study NCT05449457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-Octyl cyanoacrylate
Description: Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
Study NCT04804891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Therapy
Description: Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
Study NCT04707638 — intervention group
Intervention type: OTHER
Intervention: No intervention used
Description: No intervention used
Study NCT05563493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group, Chair-Based Exercise Training
Description: The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized.
Study NCT05563493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group, Breathing exercise
Description: Breathing exercise will be applied to the patients every day they are hospitalized.
Study NCT05340504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
Study NCT05340504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
Study NCT05172544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-002 YFV
Description: Inactivated YFV vaccine
Study NCT05172544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NaCl 0.9%, Normal Saline
Study NCT04795479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
Study NCT04795479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to relacorilant
Description: Placebo to relacorilant capsule by mouth once daily
Study NCT04795479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet by mouth
Study NCT05305482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated stent
Description: The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
Study NCT05305482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
Study NCT05086679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings with 25-30 mm Hg pressure
Description: The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
Study NCT05086679 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Compression stockings with up to <=10 mm Hg pressure
Description: The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
Study NCT05086679 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
Study NCT05086679 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle modification
Description: All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
Study NCT06354933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological Soft Signs
Description: Neurological Soft Signs score according to the Heidelberg Manual
Study NCT04968444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation
Study NCT04968444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back Pain Workshop
Description: Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
Study NCT05431244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antiviral treatment in combination with low-dose gemcitabine
Description: -maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
Study NCT06416501 — intervention group
Intervention type: OTHER
Intervention: Mode of detection
Description: Mode of detection
Study NCT04928014 — intervention group
Intervention type: OTHER
Intervention: Schirmer Strip
Description: A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
Study NCT04836039 — intervention group
Intervention type: OTHER
Intervention: A questionnaire and scales.
Description: Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
Study NCT05292755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) Artificial Tears
Description: A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
Study NCT05292755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free, CMC-free Artificial Tears (control)
Description: A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
Study NCT05208229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: WB-MRI
Description: Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
Study NCT05258227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservational Physical Therapy and Proprioceptive Strength Training
Description: The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
Study NCT05258227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservational Physical Therapy and Core Instability Strength Training
Description: Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
Study NCT05003115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
Study NCT06228157 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine therapy
Description: The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
Study NCT06228157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine therapy
Description: The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
Study NCT06228157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06337396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WGS and transcriptome analysis
Description: In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
Study NCT06327594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound scan
Description: The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.
Study NCT06327594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT/MRI scan
Description: The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
Study NCT04673383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL026
Description: Intravenous solution
Study NCT04673383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SPL026-matched placebo
Study NCT05811065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIVF dosage
Description: Opt-IVF dosage
Study NCT05811065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional drug treament
Description: Traditional drug treatment
Study NCT06404190 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Diode laser and 3% hydrogen peroxide
Description: Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes.
Study NCT05391243 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LLETZ
Description: Large loop excision of the transformation zone
Study NCT04650633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Study NCT06278688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Precision probiotics
Description: The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
Study NCT06278688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Precision probiotics
Description: The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
Study NCT04207476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMF
Description: Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
Study NCT04207476 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
Study NCT04910984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot messages
Description: Automated personalized messages containing HIV testing-related information, motivation and skills
Study NCT04910984 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-matched educational materials
Description: Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
Study NCT06390501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks, 0.1 mg semaglutide once weekly for four weeks, 1.7 mg semaglutide once weekly for four weeks followed by 2.4 mg semaglutide once weekly for eight weeks
Study NCT06390501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous (s.c. - under the skin) injection
Study NCT06346730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses to intervention group
Description: experimental and control ,a randomized pretest-posttest study to examine
Study NCT05937464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exoskeleton ExoAthlet group
Description: This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
Study NCT05937464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lokomat Free-D group
Description: This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
Study NCT06082401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodiafiltration (HDF)
Description: Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
Study NCT06082401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ex vivo lung perfusion (EVLP)
Description: Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications.
Study NCT06082401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion (EVLP)
Description: Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications.
Study NCT04896645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digihaler Albuterol Device by TEVA
Description: Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home